Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy for dry eye: does skin tone matter?

NCT ID NCT07173530

Knowledge-focused Sponsor: University of Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether low-level light therapy (LLLT) warms the eyelids differently in people with various skin pigmentation levels who also have dry eye or meibomian gland disease. Forty adults will receive three 15-minute sessions over 1-2 weeks. Researchers will measure eyelid temperature and eye symptoms to see if skin color affects treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-level light therapy device (Essilor epi-c plus)
What this could lead to
If successful, this could help personalize dry eye treatments based on skin pigmentation.
What could go wrong
This is a small, early study with only 40 participants and no control group, so results may not apply widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to read and understand the study informed consent in English * Age 18 years or older at enrollment * Individuals with MGD based on one or more of the following clinical signs/symptoms, e.g., meibum quality score of 1-3 (Bron et al.), meibography score of 1, 2, or 3 on the Pult Meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an Ocular Surface Disease Index (OSDI) score greater than 12 points. Exclusion Criteria: * Active anterior segment pathology (e.g., bacterial conjunctivitis, microbial keratitis) * History of systemic disease associated with aqueous-deficient dry eye disease (e.g., Sjogren's syndrome) * History of corneal surgery, refractive surgery, or eyelid surgery within 6 months * History of corneal ectasia (e.g. keratoconus, Pellucid marginal degeneration) * History of ocular trauma within 6 months * History of LipiFlow, iLux, Meiboflow, IPL or LLLT within the last 12 months * Habitual use of photosensitizing medications within the last 30 days * Pregnant and/or lactating females, by self-report * Pigmented lesions, tattoos, or skin cancer in the periocular region * Unwilling to have eyes photographed or video recorded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome Meibomian Gland Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye Meibomian gland dysfunction (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Houston College of Optometry

    RECRUITING

    Houston, Texas, 77204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.